TY - JOUR
T1 - Melatonin role preventing steatohepatitis and improving liver transplantation results
AU - Esteban-Zubero, Eduardo
AU - García-Gil, Francisco Agustín
AU - López-Pingarrón, Laura
AU - Alatorre-Jiménez, Moisés Alejandro
AU - Ramírez, José Manuel
AU - Tan, Dun Xian
AU - García, José Joaquín
AU - Reiter, Russel J.
N1 - Funding Information:
This work was supported by grants from the ‘Gobierno de Aragón’ (Aging and Oxidative Stress Physiology, Grant No. B40) and from the ‘Instituto de Salud Carlos III’ (RD12/0043/0035). Special acknowledgment also is given to the Department of Cellular and Structural Biology of University of Texas Health Science Center at San Antonio for hosting E.E.Z. during the preparation of this review.
Publisher Copyright:
© 2016, Springer International Publishing.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Liver steatosis is a prevalent process that is induced due to alcoholic or non-alcoholic intake. During the course of these diseases, the generation of reactive oxygen species, followed by molecular damage to lipids, protein and DMA occurs generating organ cell death. Transplantation is the last-resort treatment for the end stage of both acute and chronic hepatic diseases, but its success depends on ability to control ischemia–reperfusion injury, preservation fluids used, and graft quality. Melatonin is a powerful endogenous antioxidant produced by the pineal gland and a variety of other because of its efficacy in organs; melatonin has been investigated to improve the outcome of organ transplantation by reducing ischemia–reperfusion injury and due to its synergic effect with organ preservation fluids. Moreover, this indolamine also prevent liver steatosis. That is important because this disease may evolve leading to an organ transplantation. This review summarizes the observations related to melatonin beneficial actions in organ transplantation and ischemic–reperfusion models.
AB - Liver steatosis is a prevalent process that is induced due to alcoholic or non-alcoholic intake. During the course of these diseases, the generation of reactive oxygen species, followed by molecular damage to lipids, protein and DMA occurs generating organ cell death. Transplantation is the last-resort treatment for the end stage of both acute and chronic hepatic diseases, but its success depends on ability to control ischemia–reperfusion injury, preservation fluids used, and graft quality. Melatonin is a powerful endogenous antioxidant produced by the pineal gland and a variety of other because of its efficacy in organs; melatonin has been investigated to improve the outcome of organ transplantation by reducing ischemia–reperfusion injury and due to its synergic effect with organ preservation fluids. Moreover, this indolamine also prevent liver steatosis. That is important because this disease may evolve leading to an organ transplantation. This review summarizes the observations related to melatonin beneficial actions in organ transplantation and ischemic–reperfusion models.
KW - Alcohol
KW - Ischemia–reperfusion injury
KW - Liver transplantation
KW - Melatonin
KW - Preservation fluids
KW - Steatosis
UR - http://www.scopus.com/inward/record.url?scp=84962298587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962298587&partnerID=8YFLogxK
U2 - 10.1007/s00018-016-2185-2
DO - 10.1007/s00018-016-2185-2
M3 - Review article
C2 - 27022943
AN - SCOPUS:84962298587
VL - 73
SP - 2911
EP - 2927
JO - Cellular and Molecular Life Sciences
JF - Cellular and Molecular Life Sciences
SN - 1420-682X
IS - 15
ER -